Key clinical point: Earlier identification of at-risk individuals with the urinary biomarker CKD273 could be useful in guiding targeted preventive therapy.
Major finding: Progression to microalbuminuria was significantly more common in patients with high-risk CKD273 patterns, compared with those with low-risk patterns (28% vs. 9%).
Study details: A multicenter, prospective, observational study and embedded randomized, controlled trial (PRIORITY) of 1,775 participants.
Disclosures: The study was supported by the European Union Seventh Framework Programme. Dr. Tofte had no financial conflicts to disclose. Several other authors disclosed relationships with multiple companies, including Amgen, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, and Sanofi. Dr. Nicholas had no financial conflicts to disclose.
Tofte N et al. Lancet Diabetes Endocrinol. 2020 Mar 2.; Nicholas SB. Lancet Diabetes Endocrinol. 2020 Mar 2. .